Boardroom Media

Medlab Clinical Ltd (ASX: MDC) is pleased to announce the NanoCBD™ update. Medlab’s NanoCBD™ product has been developed out of our US operations, with manufacturing underway at a licenced FDA facility, and has already received its first export order and deposit for 1,500 units to Hong Kong.

Boardroom.Media speaks to Medlab Clinical Limited (ASX:MDC) CEO Sean Hall about Cannabis acting in the world of traditional pharmaceuticals. Medlab is an Australian life science company listed on the Australian Securities Exchange specialising in novel therapeutic discoveries to counter today’s chronic disease and improve quality of life. Medlab stands in the medical and pharmacy community that supports and promotes the health and safety of drug availability on the Australian market.

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based specialist Medical Cannabis company with its principal business goal to produce and supply high quality Cannabinoid based products for the emergent medical markets in Europe, North America and Australasia. The company is built on the vision to be an international pioneer in the biopharmaceutical industry. We discussed the booming Cannabis market and why investors should consider cannabis stocks today.

Boardroom.Media speaks to MMJ Group Holdings Limited (MMJ) director Mike Curtis about the future of the Cannabis market. MMJ Group Holdings Limited owns a portfolio of cannabis sector investments. MMJ aims to invest across the full range of cannabis-related sectors including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, R&D and retail. The legal market in Canada is fully recreational and it is a highly regulated market. MMJ is expecting Australia to be focused in the medicinal market, focusing generally on the clinics. MMJ looks to the higher quality regulated market in terms of not the recreational but really providing quality products to professionals.

MGC Pharmaceuticals Ltd (ASX:MXC) is a European based ‘Seed to Medicine’ bio-pharma company focused on developing and commercialising phytocannabinoid derived medicines, is pleased to announce it has received formal approval for the sale of CannEpil® in Ireland following the recommendation by the Health Products Regulatory Authority (HPRA), CannEpil® is one of MGC Pharma’s Investigational Medicinal Product’s (IMP) to treat drug resistant epilepsy. MGC Pharmaceuticals also announced it has signed a binding term sheet (the ‘Term Sheet’) with established Brazilian business services company, BRASILINVEST Global Business and Development (‘BrasilInvest’) to establish a Joint Venture Company (‘JV Co’) for the dedicated retail sales and marketing of MGC Pharma products into key Brazil and Latin American markets. The JV Co is to be incorporated as a 50% (BrasilInvest)/50% (MGC Pharma) ownership structure.

MGC Pharmaceuticals Ltd (ASX: MXC) is a European-based specialist Medical Cannabis company with its principal business goal to produce and supply high quality Cannabinoid based products for the emergent medical markets in Europe, North America and Australasia. The company is built on the vision to be an international pioneer in the biopharmaceutical industry. We discussed the booming Cannabis market and why investors should consider cannabis stocks today.

John Huggart Speaks to Boardroom Media's Will Canty 

Boardroom Media's Will Canty speaks with Boardroom Media's John Huggart.

Star Farmer is a company foundered on a propriety platform technology which is a kind of a polymer called a dengrimer.

Chief Commercial Officer Darryl Garber speaks with Boardroom Media about ELMO's cloud based HR software.